TREATMENT OF MAJOR ADVERSE CARDIAC EVENTS AND ACUTE CORONARY SYNDROME USING THE SECRETARY PHOSPHOLIPASE A (SPLA) INHIBITOR OR THE COMBINED METHODS OF TREATMENT WITH THE INHIBITOR TESTS

摘要

The introduction of sPLA inhibitors in combination with statins has been found to reduce the incidence of major adverse cardiac events (MACE), inflammation biomarkers and LDL-C levels in individuals who have recently suffered an ACS-indicating event to a much greater extent than statins alone. These results were unexpected, given previous results that showed that statins alone are not sufficient to satisfactorily reduce MACE and inflammation in this high-risk population. Thus, provided herein are methods of treating MACE, treating ACS, inhibiting inflammation, and lowering cholesterol in an individual who has recently suffered a case of ACS by administering one or more sPLA inhibitors alone or in combination with one or more statins.